Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- SymBio Earns Sales Milestone for Bendamustine from Taiwanese Firm
July 13, 2016
- “Limited Potential for Growth through Domestic Business Alone” Is Reason for Acquiring US Generic Maker: Nichi-Iko Pres.
July 13, 2016
- AnGes MG to Develop Chimera Decoy for World’s 1st Simultaneous Inhibition of Multiple Targets as Anti-Inflammatory Therapies
July 13, 2016
- Ono Gets Rights to Celyad’s Allogeneic CAR T-cell Therapy
July 12, 2016
- Kyorin to Copromote Allergy Drug Desloratadine with Kaken
July 12, 2016
- Medreich’s Japan-Bound Generics Plant in India Completed: Meiji
July 12, 2016
- Nichi-Iko to Buy Sagent for US$736 Million
July 12, 2016
- 1st Patients Randomized in PII Cell Therapy Trial for Traumatic Brain Injury: SanBio
July 12, 2016
- Ethical Drug Sales Up 5.8% in May: Crecon Report
July 12, 2016
- Kyorin Eager to Resurrect Drug Discovery Prowess, Says President
July 11, 2016
- Nippon Chemiphar to Boost Generic Production to 2 Billion Tablets by FY2018: President
July 11, 2016
- NTD Collaboration with Astellas Began by Coincidence: Merck Global Health R&D Chief
July 11, 2016
- Adcetris Approved for Add’l Indication in Europe: Takeda
July 8, 2016
- Pfizer Adjusting Shipments of Certain Olanzapine Generics Due to Shortage
July 8, 2016
- Heptares Earns US$10 Million Milestone on 1st Dosing of Immuno-Oncology Candidate
July 7, 2016
- Parkinson’s Drug Opicapone Approved in Europe: Ono
July 7, 2016
- AnGes MG Reports Disappointing Data for Nucleic Acid Drug, Filing Plan Now Back on Drawing Board
July 7, 2016
- Kyorin Anticipates Annual Growth of “at Least 3%” through New Drugs Despite Patent Loss for Kipres: President
July 7, 2016
- Oncolys, Nagoya Univ. to Jointly Research Combo Therapy of OBP-301, Checkpoint Inhibitor
July 6, 2016
- Taisho Acquires 24.5% Stake in Vietnamese Drug Maker
July 6, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…